tiprankstipranks

RxSight price target lowered to $36 from $60 at BofA

BofA lowered the firm’s price target on RxSight (RXST) to $36 from $60 and keeps a Buy rating on the shares. Shares are down 61% since hitting all-time highs in June 2024 as the stock re-rated after inline Q3/Q4 results and a generally tougher macro environment for high growth, not yet profitable medtech companies, the analyst tells investors in a research note. The firm thinks the stock could be rangebound near-term with only an inline Q1.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue